M Taherianfard1, M Shariaty. 1. Ebne Sina Hospital, School of Veterinary Medicine, Shiraz University, Shiraz, Iran. taherian@hafez.shirazu.ac.ir
Abstract
BACKGROUND: Recent studies have implicated the abnormalities in the gamma-aminobutyric acid (GABA) neurotransmmiter system in the pathophysiology of schizophrenia. There are also evidences indicating that steroids of central or peripheral origin may modulate GABAergic system through direct interaction with the GABAA receptor complex. These raise the possibility that alternations in serum steroid hormones may contribute to the pathophysiological process in the schizophrenia. AIMS: The purposes of this study were first, to determine whether alternations in steroid serum levels occur in schizophrenic patients, and secondly to determine whether such alternations normalize with clinical improvement. METHODS AND MATERIAL: Serum concentrations of testosterone (T), estradiol (E), progesterone (P) and cortisol (C) were determined in male schizophrenic patients (N = 49) before treatment, during treatment and after recovery and in age-matched healthy male subjects (N = 17). All steroid hormones were assayed by ELISA method. STATISTICAL ANALYSIS USED: Differences in steroids concentrations between groups were assayed by One-Way Analysis of Variance (ANOVA), followed by Tukey's post hoc test. The level of significance was considered at P < 0.05. RESULTS AND CONCLUSION: The serum concentrations of E, P and C were significantly (P < 0.05) lower in male schizophrenic patients in all three stages of the study, compared with healthy subjects. Serum concentrations of T were significantly (P < 0.05) lower in male schizophrenic patients before and during treatment, but not after recovery, compared with healthy subjects. These findings support the occurrence of abnormal steroid concentrations in schizophrenic patients and suggest that lower T level in this disorder is related to the illness and normalizes with remission, while trait-related factors may contribute to lower serum E and C levels in schizophrenia.
BACKGROUND: Recent studies have implicated the abnormalities in the gamma-aminobutyric acid (GABA) neurotransmmiter system in the pathophysiology of schizophrenia. There are also evidences indicating that steroids of central or peripheral origin may modulate GABAergic system through direct interaction with the GABAA receptor complex. These raise the possibility that alternations in serum steroid hormones may contribute to the pathophysiological process in the schizophrenia. AIMS: The purposes of this study were first, to determine whether alternations in steroid serum levels occur in schizophrenicpatients, and secondly to determine whether such alternations normalize with clinical improvement. METHODS AND MATERIAL: Serum concentrations of testosterone (T), estradiol (E), progesterone (P) and cortisol (C) were determined in male schizophrenicpatients (N = 49) before treatment, during treatment and after recovery and in age-matched healthy male subjects (N = 17). All steroid hormones were assayed by ELISA method. STATISTICAL ANALYSIS USED: Differences in steroids concentrations between groups were assayed by One-Way Analysis of Variance (ANOVA), followed by Tukey's post hoc test. The level of significance was considered at P < 0.05. RESULTS AND CONCLUSION: The serum concentrations of E, P and C were significantly (P < 0.05) lower in male schizophrenicpatients in all three stages of the study, compared with healthy subjects. Serum concentrations of T were significantly (P < 0.05) lower in male schizophrenicpatients before and during treatment, but not after recovery, compared with healthy subjects. These findings support the occurrence of abnormal steroid concentrations in schizophrenicpatients and suggest that lower T level in this disorder is related to the illness and normalizes with remission, while trait-related factors may contribute to lower serum E and C levels in schizophrenia.
Authors: Emilio Fernandez-Egea; Clemente García-Rizo; Brian Miller; Eduard Parellada; Azucena Justicia; Miguel Bernardo; Brian Kirkpatrick Journal: Psychosom Med Date: 2011-09-23 Impact factor: 4.312
Authors: H Y Chan; C J Chang; S C Chiang; J J Chen; C H Chen; H J Sun; H G Hwu; M S Lai Journal: J Psychopharmacol Date: 2008-09-18 Impact factor: 4.153